These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 39503729)

  • 1. Single-cell multiomics analysis of chronic myeloid leukemia links cellular heterogeneity to therapy response.
    Warfvinge R; Geironson Ulfsson L; Dhapola P; Safi F; Sommarin M; Soneji S; Hjorth-Hansen H; Mustjoki S; Richter J; Thakur RK; Karlsson G
    Elife; 2024 Nov; 12():. PubMed ID: 39503729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML.
    Warfvinge R; Geironson L; Sommarin MNE; Lang S; Karlsson C; Roschupkina T; Stenke L; Stentoft J; Olsson-Strömberg U; Hjorth-Hansen H; Mustjoki S; Soneji S; Richter J; Karlsson G
    Blood; 2017 Apr; 129(17):2384-2394. PubMed ID: 28122740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leukemic stem cell persistence in chronic myeloid leukemia patients in deep molecular response induced by tyrosine kinase inhibitors and the impact of therapy discontinuation.
    Chomel JC; Bonnet ML; Sorel N; Sloma I; Bennaceur-Griscelli A; Rea D; Legros L; Marfaing-Koka A; Bourhis JH; Ame S; Guerci-Bresler A; Rousselot P; Turhan AG
    Oncotarget; 2016 Jun; 7(23):35293-301. PubMed ID: 27167108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Leukemic stem cells shall be searched in the bone marrow before "tyrosine kinase inhibitor-discontinuation" in chronic myeloid leukemia.
    Ilhan O; Narli Ozdemir Z; Dalva K; Arslan A; Okay Ozgeyik M; Ipek S; Saydam G; Haznedaroglu IC
    Int J Lab Hematol; 2021 Oct; 43(5):1110-1116. PubMed ID: 33834631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells.
    Neviani P; Harb JG; Oaks JJ; Santhanam R; Walker CJ; Ellis JJ; Ferenchak G; Dorrance AM; Paisie CA; Eiring AM; Ma Y; Mao HC; Zhang B; Wunderlich M; May PC; Sun C; Saddoughi SA; Bielawski J; Blum W; Klisovic RB; Solt JA; Byrd JC; Volinia S; Cortes J; Huettner CS; Koschmieder S; Holyoake TL; Devine S; Caligiuri MA; Croce CM; Garzon R; Ogretmen B; Arlinghaus RB; Chen CS; Bittman R; Hokland P; Roy DC; Milojkovic D; Apperley J; Goldman JM; Reid A; Mulloy JC; Bhatia R; Marcucci G; Perrotti D
    J Clin Invest; 2013 Oct; 123(10):4144-57. PubMed ID: 23999433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells.
    Bolton-Gillespie E; Schemionek M; Klein HU; Flis S; Hoser G; Lange T; Nieborowska-Skorska M; Maier J; Kerstiens L; Koptyra M; Müller MC; Modi H; Stoklosa T; Seferynska I; Bhatia R; Holyoake TL; Koschmieder S; Skorski T
    Blood; 2013 May; 121(20):4175-83. PubMed ID: 23543457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia.
    Herrmann H; Sadovnik I; Cerny-Reiterer S; Rülicke T; Stefanzl G; Willmann M; Hoermann G; Bilban M; Blatt K; Herndlhofer S; Mayerhofer M; Streubel B; Sperr WR; Holyoake TL; Mannhalter C; Valent P
    Blood; 2014 Jun; 123(25):3951-62. PubMed ID: 24778155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overcoming BCR::ABL1 dependent and independent survival mechanisms in chronic myeloid leukaemia using a multi-kinase targeting approach.
    Busch C; Mulholland T; Zagnoni M; Dalby M; Berry C; Wheadon H
    Cell Commun Signal; 2023 Nov; 21(1):342. PubMed ID: 38031192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infliximab therapy together with tyrosine kinase inhibition targets leukemic stem cells in chronic myeloid leukemia.
    Herrmann O; Kuepper MK; Bütow M; Costa IG; Appelmann I; Beier F; Luedde T; Braunschweig T; Koschmieder S; Brümmendorf TH; Schemionek M
    BMC Cancer; 2019 Jul; 19(1):658. PubMed ID: 31272418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic myeloid leukemia stem cells: targeting therapeutic implications.
    Mojtahedi H; Yazdanpanah N; Rezaei N
    Stem Cell Res Ther; 2021 Dec; 12(1):603. PubMed ID: 34922630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors.
    Pietarinen PO; Eide CA; Ayuda-Durán P; Potdar S; Kuusanmäki H; Andersson EI; Mpindi JP; Pemovska T; Kontro M; Heckman CA; Kallioniemi O; Wennerberg K; Hjorth-Hansen H; Druker BJ; Enserink JM; Tyner JW; Mustjoki S; Porkka K
    Oncotarget; 2017 Apr; 8(14):22606-22615. PubMed ID: 28186983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia.
    Eiring AM; Page BDG; Kraft IL; Mason CC; Vellore NA; Resetca D; Zabriskie MS; Zhang TY; Khorashad JS; Engar AJ; Reynolds KR; Anderson DJ; Senina A; Pomicter AD; Arpin CC; Ahmad S; Heaton WL; Tantravahi SK; Todic A; Moriggl R; Wilson DJ; Baron R; O'Hare T; Gunning PT; Deininger MW
    Leukemia; 2015 Mar; 29(3):586-597. PubMed ID: 25134459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of chronic myeloid leukemia stem cells and hematopoietic stem cells by global proteomic analysis.
    Zhou S; Zhu X; Liu W; Cheng F; Zou P; You Y; Xiao Y; Guo A; Zhu X
    Biochem Biophys Res Commun; 2020 Feb; 522(2):362-367. PubMed ID: 31767149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of tyrosine kinase inhibitors on a mouse chronic myeloid leukemia model and chronic myeloid leukemia stem cells.
    Tanaka Y; Fukushima T; Mikami K; Adachi K; Fukuyama T; Goyama S; Kitamura T
    Exp Hematol; 2020 Oct; 90():46-51.e2. PubMed ID: 32910995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone marrow niche trafficking of miR-126 controls the self-renewal of leukemia stem cells in chronic myelogenous leukemia.
    Zhang B; Nguyen LXT; Li L; Zhao D; Kumar B; Wu H; Lin A; Pellicano F; Hopcroft L; Su YL; Copland M; Holyoake TL; Kuo CJ; Bhatia R; Snyder DS; Ali H; Stein AS; Brewer C; Wang H; McDonald T; Swiderski P; Troadec E; Chen CC; Dorrance A; Pullarkat V; Yuan YC; Perrotti D; Carlesso N; Forman SJ; Kortylewski M; Kuo YH; Marcucci G
    Nat Med; 2018 May; 24(4):450-462. PubMed ID: 29505034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Residual Peripheral Blood CD26
    Bocchia M; Sicuranza A; Abruzzese E; Iurlo A; Sirianni S; Gozzini A; Galimberti S; Aprile L; Martino B; Pregno P; Sorà F; Alunni G; Fava C; Castagnetti F; Puccetti L; Breccia M; Cattaneo D; Defina M; Mulas O; Baratè C; Caocci G; Sica S; Gozzetti A; Luciano L; Crugnola M; Annunziata M; Tiribelli M; Pacelli P; Ferrigno I; Usala E; Sgherza N; Rosti G; Bosi A; Raspadori D
    Front Oncol; 2018; 8():194. PubMed ID: 29900128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapy Resistance and Disease Progression in CML: Mechanistic Links and Therapeutic Strategies.
    Ng JJ; Ong ST
    Curr Hematol Malig Rep; 2022 Dec; 17(6):181-197. PubMed ID: 36258106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells.
    Salati S; Salvestrini V; Carretta C; Genovese E; Rontauroli S; Zini R; Rossi C; Ruberti S; Bianchi E; Barbieri G; Curti A; Castagnetti F; Gugliotta G; Rosti G; Bergamaschi M; Tafuri A; Tagliafico E; Lemoli R; Manfredini R
    Oncotarget; 2017 Jul; 8(30):49451-49469. PubMed ID: 28533480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. System analysis of Huang-Lian-Jie-Du-Tang and their key active ingredients for overcoming CML resistance by suppression of leukemia stem cells.
    Huang G; Yin Z; Wang X; Wen Z; Su R; Li C; Liu Y; Yang J; Hu H; Nie H; Zeng X; Fei J
    Phytomedicine; 2023 Aug; 117():154918. PubMed ID: 37329755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variable behavior of iPSCs derived from CML patients for response to TKI and hematopoietic differentiation.
    Bedel A; Pasquet JM; Lippert E; Taillepierre M; Lagarde V; Dabernat S; Dubus P; Charaf L; Beliveau F; de Verneuil H; Richard E; Mahon FX; Moreau-Gaudry F
    PLoS One; 2013; 8(8):e71596. PubMed ID: 24058405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.